Sale!

DNAH9 Gene Primary Ciliary Dyskinesia DNAH9 Related Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The DNAH9 gene plays a crucial role in the proper functioning of cilia, which are microscopic, hair-like structures on the surface of cells. Mutations in the DNAH9 gene can lead to a condition known as Primary Ciliary Dyskinesia (PCD), a rare genetic disorder that affects the respiratory tract, fertility, and can cause situs inversus (a condition where the major visceral organs are reversed or mirrored from their normal positions).

The DNAH9-related genetic test is a specialized diagnostic tool designed to identify mutations in the DNAH9 gene, providing crucial information for the diagnosis and management of PCD. This test is particularly important for individuals showing symptoms of PCD or those with a family history of the condition, as early diagnosis can lead to better management of the symptoms and improve quality of life.

Conducted at DNA Labs UAE, a leading facility in genetic testing, the test offers a comprehensive analysis of the DNAH9 gene. The cost of the test is 4400 AED, reflecting the intricate technology and expertise required to accurately identify the mutations associated with the condition. Through this testing, individuals and families can gain valuable insights into their genetic health, enabling informed decisions regarding treatment and management of Primary Ciliary Dyskinesia.

Description

DNAH9 Gene Primary ciliary dyskinesia DNAH9 related Genetic Test

Test Name: DNAH9 Gene Primary ciliary dyskinesia DNAH9 related Genetic Test

Components: NGS Technology

Price: 4400.0 AED

Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card

Report Delivery: 3 to 4 Weeks

Test Type: Ear Nose Throat Disorders

Doctor: ENT Doctor

Test Department: Genetics

Pre Test Information: Clinical History of Patient who is going for SLC52A3 Gene Brown-Vialetto-Van Laere syndrome 1 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with SLC52A3 Gene Brown-Vialetto-Van Laere syndrome 1 NGS Genetic DNA Test gene SLC52A21

Test Details: The DNAH9 gene is associated with a condition called primary ciliary dyskinesia (PCD). PCD is a rare genetic disorder that affects the structure and function of cilia, which are hair-like structures found on the surface of cells in the respiratory tract, fallopian tubes, and other organs. The DNAH9 gene provides instructions for making a protein called dynein axonemal heavy chain 9. This protein is a component of the dynein complex, which plays a crucial role in the movement of cilia. Mutations in the DNAH9 gene can disrupt the normal functioning of cilia, leading to the development of PCD.

NGS (Next-Generation Sequencing) genetic testing is a type of genetic testing that uses advanced sequencing technology to analyze multiple genes simultaneously. In the context of PCD, NGS genetic testing can identify mutations in the DNAH9 gene and other genes known to be associated with the condition. NGS genetic testing for DNAH9-related PCD can help in the diagnosis of the condition, as well as in identifying carriers of the gene mutation. It can also provide information about the specific mutation present, which can be useful for understanding the prognosis and potential treatment options for individuals with PCD.

It is important to note that genetic testing for PCD is typically done in conjunction with other diagnostic tests, such as measurement of ciliary function and structure, as well as clinical evaluation of symptoms. Genetic testing alone may not be sufficient for a definitive diagnosis of PCD. Genetic counseling is also recommended before and after genetic testing to help individuals understand the implications of the test results and make informed decisions about their healthcare.

Test Name	DNAH9 Gene Primary ciliary dyskinesia DNAH9 related Genetic Test
Components
Price	4400.0 AED
Sample Condition	Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery	3 to 4 Weeks
Method	NGS Technology
Test type	Ear Nose Throat Disorders
Doctor	ENT Doctor
Test Department:	Genetics
Pre Test Information	Clinical History of Patient who is going for SLC52A3 Gene Brown-Vialetto-Van Laere syndrome 1 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with SLC52A3 Gene Brown-Vialetto-Van Laere syndrome 1 NGS Genetic DNA Test gene SLC52A21
Test Details	The DNAH9 gene is associated with a condition called primary ciliary dyskinesia (PCD). PCD is a rare genetic disorder that affects the structure and function of cilia, which are hair-like structures found on the surface of cells in the respiratory tract, fallopian tubes, and other organs. The DNAH9 gene provides instructions for making a protein called dynein axonemal heavy chain 9. This protein is a component of the dynein complex, which plays a crucial role in the movement of cilia. Mutations in the DNAH9 gene can disrupt the normal functioning of cilia, leading to the development of PCD. NGS (Next-Generation Sequencing) genetic testing is a type of genetic testing that uses advanced sequencing technology to analyze multiple genes simultaneously. In the context of PCD, NGS genetic testing can identify mutations in the DNAH9 gene and other genes known to be associated with the condition. NGS genetic testing for DNAH9-related PCD can help in the diagnosis of the condition, as well as in identifying carriers of the gene mutation. It can also provide information about the specific mutation present, which can be useful for understanding the prognosis and potential treatment options for individuals with PCD. It is important to note that genetic testing for PCD is typically done in conjunction with other diagnostic tests, such as measurement of ciliary function and structure, as well as clinical evaluation of symptoms. Genetic testing alone may not be sufficient for a definitive diagnosis of PCD. Genetic counseling is also recommended before and after genetic testing to help individuals understand the implications of the test results and make informed decisions about their healthcare.